One such strategy rests on a compelling preclinical rationale. Laboratory studies have suggested that angiogenesis inhibitors, drugs that starve tumors of their blood supply by blocking vascular signaling pathways, may act synergistically with CDK4/6 inhibitors when the two classes are combined. The biological logic is attractive: vascular normalization and CDK4/6 blockade could, in theory, cooperate to suppress tumor growth more effectively than either approach alone. However, translating preclinical synergy into clinical benefit has historically proven difficult in oncology, and clinical data on this particular combination remained sparse. To address that evidence gap, a team of Chinese investigators designed an early-phase trial to test whether adding an angiogenesis inhibitor to the established backbone of a CDK4/6 inhibitor plus fulvestrant, a selective estrogen receptor degrader, could deliver superior outcomes for patients with hormone receptor-positive, HER2-negative advanced breast cancer.

The study, led by Dr. Min Yan of the Department of Breast Disease at Henan Cancer Hospital and The Affiliated Cancer Hospital of Zhengzhou University, was an investigator-initiated, single-center, open-label phase Ib/II trial evaluating the triple combination of famitinib, a multitargeted antiangiogenic tyrosine kinase inhibitor, dalpiciclib, a domestically developed CDK4/6 inhibitor, and fulvestrant. “Although preclinical evidence supports synergistic effects between antiangiogenic therapies and CDK4/6 inhibitors, clinical data on this combination remain limited,” Dr. Yan noted, explaining the motivation for the study. “We therefore initiated this trial to determine whether this regimen could address the substantial unmet clinical needs of the target patient population.” The findings were published online in the Chinese Medical Journal on July 7, 2026, and they offer a sobering, carefully documented lesson in the challenges of modern combination drug development.

A total of 46 eligible patients were enrolled across the two study phases. The trial began with a dose-finding phase Ib component involving 18 patients, in which the investigators systematically escalated and evaluated the tolerability of the three-drug regimen. This work established a recommended phase II dose of famitinib 10 milligrams daily combined with dalpiciclib 100 milligrams daily, administered alongside standard fulvestrant. That the dose of dalpiciclib had to be set at 100 milligrams, at the lower end of its commonly used range, foreshadowed the tolerability issues that would later dominate the safety picture. The phase II portion then enrolled 28 additional patients to assess the antitumor activity of the combination at the established dose.

The initial efficacy signals were, on their face, encouraging. In the phase II cohort, the confirmed objective response rate reached 51.9 percent, meaning that more than half of the evaluable patients experienced measurable tumor shrinkage, while the disease control rate stood at 92.6 percent, indicating that the vast majority of patients achieved at least stable disease. These figures satisfied the prespecified efficacy threshold for the first-stage analysis, and the response rate was numerically higher than benchmarks typically reported for standard first-line regimens in comparable populations. Had the trial stopped there, the narrative might have been one of cautious optimism for a new frontline option in this common breast cancer subtype.

But progression-free survival, the metric that ultimately determines whether a regimen changes clinical practice, told a different story. The median progression-free survival in the phase II cohort was 15.7 months, which failed to demonstrate any advantage over currently available standard first-line treatments. For context, the CDK4/6 inhibitor ribociclib combined with fulvestrant has shown a median progression-free survival of 20.5 months in similar patient populations, nearly five months longer than the triple combination achieved. “The ORR observed in our trial was numerically higher, but this did not translate into a longer PFS,” Dr. Yan explained. “This may be attributable to the high rate of dose reductions necessitated by adverse events, which likely compromised dose intensity and long-term efficacy.” In other words, the regimen may have been biologically active, but patients could not tolerate it at full intensity long enough for that activity to translate into durable disease control.

The safety analysis laid bare the central problem. The most common grade 3 or higher treatment-related adverse events were hematologic, meaning they affected blood cell counts. Decreased neutrophil counts, a condition known as neutropenia that increases susceptibility to serious infections, occurred in 96.4 percent of patients at grade 3 or worse. Decreased leukocyte counts affected 75.0 percent of patients, and decreased platelet counts, which impair blood clotting, were observed in 10.7 percent. Nearly every patient in the trial required a dose reduction because of adverse events. The investigators concluded that the addition of famitinib exacerbated hematologic toxicities beyond levels seen with either agent alone, forcing the frequent dose reductions that likely undermined the regimen’s long-term efficacy. They speculated that a potential pharmacokinetic culprit was a CYP3A4-mediated drug-drug interaction between famitinib and dalpiciclib, since CYP3A4 is a liver enzyme responsible for metabolizing many drugs, and inhibition of this pathway by famitinib could have elevated dalpiciclib exposure and intensified its bone marrow suppression.

The trial also incorporated exploratory biomarker analyses aimed at identifying which patients might benefit most from the combination. These analyses examined outcomes according to mutation status for PIK3CA, a gene frequently altered in hormone receptor-positive breast cancer and a validated therapeutic target, and for BRCA1/2, the well-known DNA repair genes. The results did not reveal statistically significant differences in outcomes based on either mutation status, although patients carrying PIK3CA or BRCA1/2 mutations did show numerically shorter progression-free survival compared with those whose tumors were wild-type at these loci. Given the small sample size, these exploratory findings are hypothesis-generating at best, but they provide useful signals for future studies attempting to define biomarker-selected populations for antiangiogenic combinations.

Following a comprehensive benefit-risk assessment, the investigators made the decision to terminate patient enrollment early. The combination of significant hematologic toxicity, near-universal dose reductions, and the absence of clear superiority over established standard therapies meant that continuing the trial could not be justified for the patient population it was designed to serve. This early termination, while disappointing, reflects the scientific integrity of the trial design: the study was built to detect whether the triple regimen offered genuine clinical advantage, and when that advantage failed to materialize, the responsible course was to stop rather than expose additional patients to a more toxic regimen without proven benefit. Such transparent reporting of negative and ambiguous results remains essential to the rational evolution of combination strategies in oncology.

Despite the outcome, Dr. Yan and her colleagues believe the study yields important forward-looking insights. “Our findings suggest that angiogenesis inhibitors may not represent a preferred option in the frontline treatment of HR+/HER2− breast cancer, but they may have greater potential in more aggressive subtypes like triple-negative breast cancer or refractory disease,” Dr. Yan concluded. This reframing positions antiangiogenic therapy not as a failed class, but as a strategy whose value may lie elsewhere in the breast cancer spectrum, where treatment options are thinner and tumor biology is more dependent on vascular signaling. The researchers also hope the study will inform future clinical trial design, underscoring two enduring principles of oncology drug development: combination strategies must be built on rigorous attention to pharmacokinetic interactions and dose intensity, and patient selection must be grounded in biology rather than convenience. The trial was supported by a grant from the XINRUI Project of Cancer Supportive Care and Treatment Research, with famitinib and dalpiciclib supplied by Jiangsu Hengrui Pharmaceuticals and fulvestrant provided by Chia Tai Tianqing Pharmaceutical Group. For patients with hormone receptor-positive, HER2-negative advanced breast cancer, standard first-line CDK4/6 inhibitor plus endocrine therapy regimens remain the benchmark against which all new combinations must now be measured.

Subject of Research: A phase Ib/II trial of famitinib plus dalpiciclib and fulvestrant in HR-positive, HER2-negative advanced breast cancer

Article Title: Chinese Medical Journal evaluates triple regimen for HR+/HER2− advanced breast cancer

Article References: Chinese Medical Journal evaluates triple regimen for HR+/HER2− advanced breast cancer. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: breast cancer, HR-positive HER2-negative, CDK4/6 inhibitors, dalpiciclib, famitinib, fulvestrant, angiogenesis inhibitors, progression-free survival, hematologic toxicity, drug-drug interaction, CYP3A4, phase Ib/II trial

The study was designed to answer a deceptively simple question: what happens to the levels of two drugs in the body when they are given at the same time? Both anlotinib and amlodipine are taken orally, both circulate widely in the bloodstream, and both are processed by the same cellular machinery in the liver and intestine. That overlap creates the potential for what pharmacologists call a drug-drug interaction, in which one compound slows, accelerates, or otherwise alters the absorption, distribution, metabolism, or elimination of another. When that happens, a drug that is normally safe at its prescribed dose can accumulate to dangerous levels, or conversely fall below the threshold needed to work.

To investigate, the team used Sprague-Dawley rats, a standard laboratory strain weighing between 180 and 220 grams, obtained from Hunan SJA Laboratory Animal Co., Ltd. All protocols were approved by the Ethics Committee of Liuzhou People’s Hospital under approval number LRYIACUC2024008. The animals were randomly divided into three groups. The first received anlotinib alone at a dose of 6 milligrams per kilogram of body weight, delivered by oral gavage, a technique in which liquid medication is placed directly into the stomach. The second received amlodipine besylate alone at 4 milligrams per kilogram, also by gavage. The third group received both drugs simultaneously at the same doses. The researchers then drew blood samples over time and measured the concentration of each drug in plasma using a validated liquid chromatography-tandem mass spectrometry method, commonly abbreviated LC-MS/MS.

LC-MS/MS is the gold standard for this kind of work. Liquid chromatography first separates the complex mixture of molecules in a plasma sample, and tandem mass spectrometry then identifies and quantifies the target compounds with extraordinary sensitivity, detecting them at concentrations far below what older techniques could manage. From the resulting concentration-time data, the team plotted mean plasma curves and calculated pharmacokinetic parameters using non-compartmental modeling, a widely used mathematical approach that does not assume any particular structure for how the drug moves through the body. The key parameters include Cmax, the peak concentration reached in the blood; AUC, the area under the concentration-time curve, which represents total drug exposure over time; clearance, the rate at which the body removes the drug; and half-life, the time it takes for the drug concentration to fall by half.

The results were strikingly one-sided. After a single dose, rats given both drugs showed a peak amlodipine concentration 2.34 times higher than rats given amlodipine alone, and total amlodipine exposure over the observation period, measured as AUC from time zero to the last measurable time point, rose to 2.01 times the control value. Clearance, meanwhile, dropped by 64.4 percent, meaning the animals were removing amlodipine from their circulation at less than half the normal rate. All of these differences were statistically significant at the conventional threshold of P less than 0.05.

Repeated dosing told an even more dramatic story. When the drugs were given multiple times, the total amlodipine exposure extrapolated to infinity, AUC from zero to infinity, climbed to 3.30 times the value seen with amlodipine alone. The drug’s half-life stretched to 2.73 times its usual length, and clearance fell by 64.9 percent, essentially matching the single-dose reduction. In practical terms, the combination turned amlodipine from a drug the body clears steadily into one that lingers and accumulates, with each successive dose building on the residue of the last. For a medication whose therapeutic and adverse effects are directly tied to blood concentration, that kind of accumulation matters.

Anlotinib, however, marched to its own drummer. Across both the single-dose and multiple-dose experiments, none of its pharmacokinetic parameters changed significantly when amlodipine was on board, with all comparisons showing P greater than 0.05. The interaction, in other words, flows in one direction only: anlotinib profoundly reshapes amlodipine’s journey through the body, while amlodipine leaves anlotinib alone. This asymmetry is itself informative, because it suggests a specific mechanism rather than a general perturbation of the animals’ physiology.

Although the study did not directly identify the molecular culprit, the pattern is consistent with what is known about how these drugs are metabolized. Both anlotinib and amlodipine are substrates of the cytochrome P450 enzyme family, the liver’s principal drug-processing assembly line, and amlodipine in particular depends heavily on the CYP3A4 enzyme for its breakdown. Anlotinib has been reported in the literature to interact with cytochrome P450 pathways, and the authors’ finding that amlodipine clearance falls sharply while its absorption-related parameters rise points toward inhibition of amlodipine’s metabolic clearance as the most likely explanation. When CYP3A4 activity is suppressed, amlodipine lingers in the intestine and liver longer, more of it enters the bloodstream, and less of it is cleared per unit time, exactly the signature the rat data display. The authors note that the precise mechanistic confirmation would require further work, and the study was designed to characterize the interaction rather than to pin down its enzymatic basis.

Why does this matter beyond the laboratory? Anlotinib is an oral multi-target tyrosine kinase inhibitor approved in China for the treatment of several advanced cancers, including non-small cell lung cancer, small cell lung cancer, soft tissue sarcoma, and ovarian cancer, and it is increasingly used in combination regimens. Cancer patients are frequently older and carry cardiovascular comorbidities, and hypertension is among the most common. Amlodipine is a first-line antihypertensive, a dihydropyridine calcium channel blocker that relaxes blood vessels and is taken daily by tens of millions of people worldwide. The overlap between the population taking anlotinib and the population taking amlodipine is therefore substantial, and until now, the pharmacokinetic consequences of combining them had not been formally characterized in a controlled animal study.

Elevated amlodipine exposure is not a trivial side effect. Excessive amlodipine levels can cause profound hypotension, dizziness, peripheral edema, reflex tachycardia, and in severe cases cardiovascular instability, complications that are particularly dangerous for patients already weakened by cancer and its treatment. The rat findings, showing exposure increases of two- to three-fold, fall squarely in the range that clinicians would consider clinically significant. The study’s conclusion is direct: potential drug-drug interactions should be considered when anlotinib and amlodipine are co-administered in clinical practice to ensure safe and rational medication use. In a hospital setting, that could translate into closer blood pressure monitoring, dose adjustment of amlodipine, or selection of an alternative antihypertensive that does not share the same metabolic pathway.

The authors, Ruijie Xie and Yueling Huang, who share first authorship, along with Zhiling Liu, Tingyan Wei, and corresponding author Chengyu Liu, emphasize that their work was conducted in rats, and rodent pharmacokinetics do not always translate directly to humans. Doses were also chosen to characterize the interaction clearly rather than to mirror exact clinical dosing. Nevertheless, animal interaction studies of this kind are a standard and necessary early step in identifying combinations that warrant clinical vigilance, and the magnitude of the effect observed here is large enough that it would be imprudent to ignore. The study received no external funding, and the authors declare no competing interests. As anlotinib’s clinical footprint expands and as more cancer patients live long enough to require chronic cardiovascular medication, studies like this one serve as a reminder that the drugs we combine are never truly independent actors. Each prescription is a chemistry experiment conducted inside the patient, and the task of modern pharmacology is to predict the outcome before the experiment begins.

Subject of Research: Pharmacokinetic drug-drug interaction between anlotinib and amlodipine besylate in rats

Article Title: Pharmacokinetic interaction between anlotinib and amlodipine besylate in rats

Article References: Xie, R., Huang, Y., Liu, Z., Wei, T., & Liu, C. (2026). Pharmacokinetic interaction between anlotinib and amlodipine besylate in rats. BMC Pharmacology and Toxicology. https://doi.org/10.1186/s40360-026-01233-w

Image Credits: AI Generated

DOI: 10.1186/s40360-026-01233-w

Keywords: anlotinib, amlodipine, pharmacokinetics, drug-drug interaction, LC-MS/MS, rats, cytochrome P450, hypertension, cancer therapy, drug clearance, BMC Pharmacology and Toxicology, preclinical study